Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders
Related Experiment Video
Updated: Aug 21, 2026

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System
Published on: April 25, 2012
Swen Hesse1, Henryk Barthel, Johannes Schwarz
1Department of Nuclear Medicine, University Hospital, University of Leipzig, Leipzig, Germany. hessw@medizin.uni-leipzig.de
Abstract:
Alterations of central serotonergic neurotransmission, particularly changes in the presynaptically located serotonin transporter (SERT) availability, are thought to be one of the major pathomechanisms of neuropsychiatric symptoms. Modern neuroimaging techniques such as single-photon emission computed tomography and positron emission tomography employ radiolabeled tracers, which bind to SERT, and thus, allow detection of cerebral SERT availability in vivo. We review SERT imaging studies in patients with depression, anxiety disorders, eating disorders and patients with neurological diseases. We furthermore elucidate the potential of SERT imaging techniques in estimating the effect of selective serotonin reuptake-inhibitors.
